| (Values in U.S. Thousands) | Jun, 2017 | Mar, 2017 | Dec, 2016 | Sep, 2016 | Jun, 2016 |
| Sales | -9,999,000 | 0 | 0 | 0 | 2,120 |
| Sales Growth | unch | unch | unch | -100.00% | -27.89% |
| Net Income | -9,999,000 | -3,270 | -5,840 | -3,690 | -6,890 |
| Net Income Growth | -305,679.91% | +44.01% | -58.27% | +46.44% | -85.71% |
(OGXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Oncogenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011 or custirsen the lead candidate currently completing three Phase 3 clinical studies in prostate and lung cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 2 clinical trials in bladder, lung, pancreas and prostate cancers; and OGX-225 is currently in pre-clinical development.